Enveric Biosciences to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th
Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm focused on mental health and oncology, announced that Dr. Joseph Tucker, CEO, will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm focused on mental health and oncology, announced that Dr. Joseph Tucker, CEO, will present at the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021. The presentation will be available on-demand starting at 7:00 a.m. ET. This conference aims to showcase innovative treatments derived from psychedelics and synthetic cannabinoids, with Enveric's research targeting conditions like cancer-related distress and PTSD. Attendees can register to watch and schedule one-on-one meetings with management.
Details
News Market Reaction – ENVB
The recorded move for ENVB in the trading session of this news was -4.83%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NAPLES, Fla., Nov. 29, 2021 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in the H.C. Wainwright 2nd Annual Psychedelics Conference to be hosted virtually on Monday, December 6, 2021.
Dr. Tucker's corporate presentation will be available on-demand starting at 7:00 a.m. ET. Register to attend here.
For more information about the conference, or to schedule a one-on-one meeting with Enveric's management team, please contact your appropriate representative directly, or send an email to H.C. Wainwright at lk@hcwco.com, or KCSA Strategic Communications at EnvericBio@kcsa.com.
About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is an innovative biotechnology company developing a next-generation mental health and oncology treatment clinical discovery platform, leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. Enveric's robust pipeline supports drug development from the clinic to commercialization for millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD and more. For more information, please visit www.enveric.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/enveric-biosciences-to-participate-in-the-hc-wainwright-2nd-annual-psychedelics-virtual-conference-on-december-6th-301431941.html
SOURCE Enveric Biosciences
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.